The Victorian Government is working with the Commonwealth to implement a National Respiratory Syncytial Virus Mother & Infant Protection Program (RSV-MIPP) for pregnant women and infants in 2025.
What this means:
Eligible women will have access to a free maternal respiratory syncytial virus (RSV) vaccine, Abrysvo®, under the National Immunisation Program (NIP) from early 2025
A single dose of the maternal vaccine is recommended in pregnancy at 28–36 weeks' gestation to protect the infant baby fromagainst RSV
Eligible infants and young children whose mothers did not receive maternal Abrysvo® vaccine during pregnancy and those most at risk of severe RSV will have access to a free, long-acting RSV monoclonal antibody, Beyfortus™ (nirsevimab)
The RSV-MIPP will prioritise uptake of the maternal RSV vaccine, to provide the baby with passive protection against RSV during the first six months of infancy
Detailed eligibility criteria will be released soon. Please monitor the Respiratory syncytial virus (RSV) immunisation and National Immunisation Program update - RSV vaccine webpages for updates to the RSV program and clinical information for health professionals.